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Background: Experimental data have provided evidence that progenitor cells of bone marrow
(BM) origin may play a role in the fibrogenic process of the lung.
Objective: To probe the possible involvement of BM mesenchymal stem cells (MSCs) in the
pathophysiology of Idiopathic Pulmonary Fibrosis (IPF) by investigating the molecular profile
of these cells.
Design: BM MSCs were studied in 10 IPF patients and 10 healthy controls. MSCs were identified
by their immunophenotypic characteristics and their potential to differentiate towards adipo-
cytes/osteocytes/chondrocytes. We evaluated the mRNA expression of genes involved in the
lung injury of IPF, namely the vascular endothelial growth factor (VEGF), fibroblast growth
factor (FGF), transforming growth factor beta-1 (TGF-b1) and the axis stromal-cell-derived
factor-1 (SDF-1)/CXCR4 in BM MSCs using quantitative RT-PCR.
Results: The BM MSCs of IPF patients displayed normal immunophenotypic characteristics and
differentiation potential. No statistically significant difference was found between patients
and controls in VEGF and FGF mRNA expression. TGF-b1 was not expressed in either patients
or controls. A significant increase in SDF-1-TR1 and CXCR4 mRNA expression was detected in
IPF patients (1.6  1025  1.2  1025 and 3.1  107  3.1  107, respectively) compared tolmonary fibrosis; BM, bone marrow; MSCs, bone marrow mesenchymal stem cells; VEGF, vascular
last growth factor; TGF-b1, transforming growth factor beta-1; SDF-1, stromal-cell-derived factor-1;
ehydrogenase.
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1536 K.M. Antoniou et al.controls (0.32  1025  0.07  1025 and 1.67  107  0.30  107, respectively) (pZ 0.001 and
pZ 0.001, respectively) whereas SDF-1 levels in MSC supernatants were similar in patients and
controls.
Conclusions: The increased CXCR4 expression by patient MSCs suggests that the BM is probably
implicated in the pathophysiology of IPF by mobilizing MSCs in response to or preceding lung
injury. The potential role of BM MSCs in IPF is another interesting field for further investigation.
ª 2010 Elsevier Ltd. All rights reserved.Table 1 Demographic and spirometric characteristics of
IPF patients and control subjects.
Characteristics Control subjects IPF patients
Number 10 10
Sex: Male/Female 5/5 7/3
Age, median (yr) 59 (32e65) 65 (40e75)
Smokers/non smokers 6/4 8/2
FVC, (% pred) 103  14 77.3  13.0*
TLC, (% pred) 101  19 67.4  14.2*
TLCO, (% pred) 96  6 60.3  17.8*
PaO2, (mmHg) e 80.3  10.0
Values are expressed as mean þ SD and age as median (range).
*Statistically significance difference between IPF patients and healthy controls
(p < 0.05).
Abbreviations: FVC, Forced Vital Capacity; TLC, Total Lung Capacity; TLCO,
Diffusing Capacity for Carbon Monoxide; PaO2, Arterial Partial
Pressure of Oxygen.Introduction
Idiopathic Pulmonary Fibrosis (IPF), the most common and
devastating form of pulmonary fibrosis, is distinguished
from other interstitial lung diseases by important prog-
nostic implications. IPF does not respond to current medical
therapies and its clinical course is marked by inexorable
deterioration, with a mortality rate of approximately 70%
five years after diagnosis.1,2 Fibroblasts, especially in their
activated differentiated state named myofibroblasts, are
considered to be the key elements in the pathogenesis of
fibrosis.3 The hallmark lesions are the fibroblast foci rep-
resenting focal areas of active fibrogenesis featuring
vigorous fibroblast replication and exuberant extracellular
matrix deposition, which may lead to obliteration of the
distal air space.1,2
Understanding the source of lung fibroblasts and myofi-
broblasts and the mechanism of recruitment are critical
issues in the pathogenesis of fibrotic lung diseases. While
these cells were classically thought to derive exclusively
from resident lung fibroblasts, recent studies indicate that
they may originate from pulmonary epithelial cells4 or even
from extrapulmonary cellular sources.5 In this context,
a profibrotic role of bone marrow (BM) derived circulating
fibroblast like cells, has been reported.5e10 In other
studies, however, a protective rather than a profibrotic
effect of BM derived mesenchymal stem cells (MSCs) has
been indicated.11 These contradictory data suggest that the
role of BM in the pathogenesis of fibrotic lung diseases
remains unclear.
The BM MSCs are multipotent cells of non-hematopoietic
origin that may differentiate into several cell lineages of
mesenchymal tissues.12e15 These cells have been demon-
strated to participate in tissue homeostasis and repair
under the influence of appropriate signals such as the
chemokine CXCL12, also known as stromal-cell-derived
factor (SDF)-1.8 Interestingly, chronic ischemic heart
disease in experimental mice models has been associated
with reduced migratory response of BM MSCs to local SDF-1
and vascular endothelial growth factor (VEGF) stimuli.16
The role of these cells in the repair of liver injury has
also been reported.17
The aim of the current study is to investigate the
possible involvement of BM MSCs in the pathophysiology of
IPF by evaluating the mRNA expression of genes involved in
the lung injury/repair process, namely the vascular endo-
thelial growth factor (VEGF), fibroblast growth factor
(FGF), transforming growth factor beta-1 (TGF-b1) and the
CXCL12/CXCR4 ligand/receptor dyad.18 To our knowledge,
this is one of the few studies investigating the role of BM
MSCs in IPF in humans.Methods
Patients
We have studied 10 patients with IPF and 10 healthy indi-
viduals (from a previous study of the University of Crete,19
age- and sex-matched with the patients (Table 1)). Patients
were recruited from the Interstitial Lung Disease Unit (ILDU)
at the Department of Thoracic Medicine of Heraklion.
The diagnosis of IPF was made in 3 cases by surgical
biopsy (in the correct clinical context, detailed below) and
the histologic diagnosis of Usual Interstitial Pneumonia
(UIP) was obtained. In the remaining 7 cases the diagnosis
was made on the basis of clinical and high-resolution
computed tomography (HRCT) criteria: (1) bilateral basal or
widespread crackles; (2) restrictive ventilatory defect or
isolated depression of DLCO; (3) computed tomography (CT)
appearances indicative of IPF with predominantly basal and
subpleural microcystic or macrocystic honeycombing, with
variably extensive ground-glass and reticular abnormalities
but no consolidation, nodular abnormalities, or other
parenchymal abnormalities (apart from centrilobular
emphysema); and (4) no environmental exposure to
a fibrogenic agent or connective tissue disease.1 According
to the aforementioned criteria a known cause of pulmonary
fibrosis, such as a connective tissue disorder, has been
excluded by both immunologic screening and rheumato-
logical clinical evaluation.
Ethical Committee of the University of Crete has
approved the study,19 and all participants (patients and
Mesenchymal stem cells in IPF 1537control subjects) were informed on the scope of the study
and gave their written informed consent.MSC culture and identification
BM MSCs were grown from posterior iliac crest aspirates, as
previously described.19,20 In brief, BM mononuclear cells
(BMMCs) isolated with Histopaque-1077 (Sigma, Saint Louis
MO) were cultured in Dulbecco’s Modified Eagle Medium-Low
Glucose (DMEM-LG; Gibco Invitrogen, Paisley Scotland)/10%
fetal calf serum (FCS; Hyclone, Logan, Utah, USA)/100 IU/ml
penicillinestreptomycin (PS, Gibco) (MSC medium) at
a concentrationof 2105 cells/cm2 in 25cm2cultureflasks in
37 C/5%CO2 humidified atmosphere. One to three days after
seeding, floating cells were removed and the medium was
replaced by fresh MSC medium. Thereafter, attached cells
were fed with fresh medium every 3e4 days. Cells were
passagedwhen 70e90% confluencewas reached, using 0.25%
trypsin-1 mM EDTA (Gibco).
MSCs were identified by their morphologic and immu-
nophenotypic characteristics and their potential to differ-
entiate towards three different pathways, namely
adipocytes, osteocytes and chondrocytes.
MSC quantification in the BMMC fraction
A colony forming unit fibroblastic assay (CFU-F) was used to
evaluate MSC frequency within BMMCs. Briefly, day-
0 BMMCs were seeded at four different concentrations,
expanded for 14 days and CFU-F number was estimated
using linear regression analysis.
Immunophenotypic characteristics of MSCs
Trypsinized MSCs from passage-2 (P2) were immunopheno-
typically characterized by flow cytometry using anti-human
monoclonal antibodies against CD29 (4B4; Cyto-Stat/Beck-
man-Coulter, Florida, USA), anti-CD44 (J173; Immunotech/
Coulter, Marseille, France), anti-CD73 (AD2; Becton Dick-
inson-Pharmingen, San Diego, CA), anti-CDw90 (F15.42;
Immunotech/Coulter), anti-CD105 (SN6; Caltag, Burlin-
game, CA), anti-CD146 (P1H12; Becton Dickinson-Pharmin-
gen), anti-CD45 (IMMU19.2; Immunotech/Coulter) and anti-
CD34 (QBend10; Beckman-Coulter). Data were processed in
an Epics Elite flow cytometer (Coulter, Miami, FL) (Fig. 1A).
Differentiation potential of MSCs at P2
Adipogenic differentiation was induced using MSC medium
supplemented with 10%FCS/0.5 mM 1-methyl-3-butylisox-
anthine/1 mM dexamethasone/0.2 mM indomethacin/10 mg/
ml insulin. Differentiation was assessed by Oil Red O stain
and adipose fatty acid-binding protein (aP2) and peroxi-
some proliferator activated receptor-g (PPARG) mRNA
expression (Fig. 1B,C).19e21 Osteogenic differentiation was
induced using MSC medium supplemented with 0.1 mM
dexamethasone/0.15 mM ascorbate-2-phosphate/3 mM
NaH2PO4. Differentiation was assessed by alkaline phos-
phatase (ALP)/Von Kossa stain and ALP and runt-related
transcription factor 2 (RUNX2) mRNA expression
(Fig. 1D,E).19e21 For chondrogenic induction, cells were
pelleted in 15 ml tubes and cultured in DMEM-High Glucose
(Gibco), supplemented with 6.25 mg/ml insulin/6.25 mg/ml
transferrin/1.33 mg/ml linoleic acid/1.25 mg/ml bovineserum albumin/1 mM sodium pyruvate/0.17 mM ascorbate-
2-phosphate/0.1 mM dexamethasone/0.35 mM L-proline/
6.25 ng/ml selenous acid/0.01 mg/ml TGF-b3 (R&D
Systems). Differentiation was identified with Alcian blue
stain and collagen type II (COL2A1) and aggrecan (AGC1)
mRNA expression (Fig. 1F,G).19e21 RT-PCR conditions and
primer sequences for differentiation-specific gene identi-
fication have been reported elsewhere.19,21
Real-time reverse transcriptase-polymerase chain
reaction assay
MSCs at P2 were homogenized in the TRIzol reagent
(Invitrogen, Carlsband, CA), total RNA was extracted and
cDNA synthesized by reverse transcription (RT) with the
Thermoscript RT kit (Invitrogen). Peptide growth factors
mRNA expression was measured using a real-time RT-PCR
assay with SYBR-Green I. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as the internal control, in
order to normalize VEGF, TGF-b1, FGF, SDF-1 (TR1 and TR2)
and CXCR4 expression levels.22,23 The mRNA-specific
primers used are listed in Table 2.
ELISA for SDF-1
SDF-1 levels in MSC culture supernatants at P2 were eval-
uated by means of ELISA (Quantikine; R&D Systems, Minn.,
MN). The sensitivity of the assays is below 47 pg/mL.
Statistical analysis
Data were analyzed using the nonparametric Man-
neWhitney test (GraphPad Software; San Diego, CA).
Values are expressed as means  1 standard error of the
mean (SEM) and a value of p < 0.05 was considered
significant.
Results
MSC frequency in the BMMC fraction
The estimated frequency of MSCs in the BMMC fraction did
not differ significantly between patients (3.33  1.44/105
BMMCs) and controls (6.64  2.94/105 BMMCs) (pZ 0.0667)
by CFU-F analysis, suggesting normal numbers of MSCs in IPF
patients.
MSC immunophenotype and differentiation
potential
Immunophenotypic analysis of MSCs from IPF patients and
healthy controls at the end of P2 demonstrated that
cultures constituted of a homogenous cell population
positive for CD73, CD90, CD146, CD105, CD29, CD44 and
negative for CD45 and CD34 surface antigens (Fig. 1A).
P2 MSCs from both IPF patients and controls were able to
differentiate towards the adipogenic, osteogenic and
chondrogenic lineages as shown by the respective cyto-
chemical staining and differentiation-specific gene mRNA
expression (Fig. 1BeG).
Figure 1 Immunophenotypic characteristics and differentiation potential of BM MSCs in IPF. Representative plots from flow
cytometric analysis of BM MSCs from an IPF patient at P2 stained with surface monoclonal antibodies. Black filled histograms show
the positive markers and gray filled histograms depict the negative markers in comparison to the isotype-matched controls (open
histograms) (A). Differentiated BM MSCs from P2 of the same patient towards the adipogenic (B, C), osteogenic (D, E) and chon-
drogenic (F, G) lineages. Adipogenic differentiation was identified by the Oil red O stain (B) and PPRG and aP2 mRNA expression (C),
osteogenic differentiation with ALP/Von Kossa staining (D) and ALP and RUNX2 mRNA expression (E) and chondrogenic differen-
tiation with Alcian blue (F) staining and AGC1 and COL2A1 mRNA expression (G).
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We first evaluated the expression of genes implicated in the
recruitment of MSCs at sites of injury. Results from the
SDF-1 and CXCR4 mRNA expression in BM MSCs are shown in
Figs. 2 and 3, respectively. A statistically significant
increase was detected in both SDF-1-TR1 and CXCR4 mRNA
expression in IPF patients (1.6  1025  1.2  1025 and
3.1  107  3.1  107, respectively) compared to controls
(0.32  1025  0.07  1025 and 1.67  107  0.30  107,respectively) (p Z 0.001 and p Z 0.001, respectively). In
contrast, no statistically significant difference was
documented in SDF-1-TR2 mRNA expression between
patients and controls (1502.6  1477.9 and 36.9  11.4,
respectively).
Regarding the BM MSC expression of genes implicated in
the pathogenesis of lung injury in IPF, no statistically
significant difference was documented in FGF and VEGF
mRNA expression between patients (3662.0  395.3 and
1242.1  12.8, respectively) and healthy controls
Table 2 Primer sequences used for quantitative Real-time RT-PCR.
Growth factor or cytokine Primer pair Sequence (50e30) Annealing temperature (C) Product size (bp)
VEGF ATGACGAGGGCCTGGAGTGTG 60 91
CCTATGTGCTGGCCTTGGTGAG
TGF-b1 AAGGACCTCGGCTGGAAGTG 137
CCCGGGTTATGCTGGTTGTA
FGF CTGGCTATGAAGGAAGATGGA 55 149
TGCCCAGTTCGTTTCAGTG
SDF-1-T1 TGAGAGCTCGCTTTGAGTGA 55 233
CACCAGGACCTTCTGTGGAT
SDF-1-T2 CTAGTCAAGTGCGTCCACGA 55 221
GGACACACCACAGCACAAAC
CXCR4 GGTGGTCTATGTTGGCGTCT 55 229
TGGAGTGTGACAGCTTGGAG
GAPDH GGAAGGTGAAGGTCGGAGTCA 60 101
GTCATTGATGGCAACAATATCCACT
Abbreviations: VEGF, Vascular Endothelial Growth Factor; FGF2, Fibroblast Growth Factor 2; TGF-b1, Transforming growth factor beta-1;
SDF-1, Stromal-cell-Derived Factor-1; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.
Mesenchymal stem cells in IPF 1539(4162.8  1903.6 and 1045.8  41.8, respectively), whereas
TGF-b1 was not expressed in either patients or controls.
SDF-1 in MSC culture supernatants
As we found a statistically significant increase in SDF-1-TR1
but not SDF-1-TR2 mRNA expression of IPF patients
compared to controls, we measured the SDF-1 total protein
levels in MSC culture supernatants at P2 by means of ELISA.
No statistically significant difference was found between
patient and controls (3031.56  461.96 pg/mL and
4236.36  582.27 pg/mL, respectively, p Z 0.1) in SDF-1
supernatant levels. In addition, the fibrocyte attractant
chemokine CXCL12 has been found increased in plasma of
IPF patients in comparison with healthy controls
(3021.0  69.2 pg/mL and 2636.36  98.57 pg/mL,
respectively, p Z 0.01).
Discussion
IPF is a devastating disease leading to progressive lung
destruction and scarring. Previous mechanistic research hasFigure 2 SDF-1-TR1 and SDF-1-TR2 mRNA expression in IPF (N Z
were higher in IPF patients compared to controls (P Z 0.001) (B)
patients and controls (P > 0.05).been mainly focused on the local fibroproliferative process.
However, experimental data have provided evidence that
progenitor cells of BM origin may play a crucial role in the
fibrogenetic process. The aim of the current study was to
investigate the possible involvement of BM MSCs in the
pathogenesis of IPF in humans.
We found that the frequency of MSCs within BMMCs did
not differ between patients and controls, although the lack
of statistical significance may results from lack of statistical
power. Our findings suggest that patients with IPF have
rather normal BM MSCs reserves, in agreement with
previous report from our institute.20 In detail, recent data
from a larger study population showed that MSCs from RA
patients and age-/sex-matched healthy individuals were
similar in frequency, differentiation potential, survival,
immunophenotypic characteristics and protein profile.
It has been reported that MSC can produce a variety of
cytokines and chemokines that play a role in the regulation
of cell migratory properties.24e26 In this respect, MSCs have
been shown to express a restricted pattern of chemokine
receptors, including CXCR4, allowing them to migrate to
tissues upon specific chemotactic triggers.27e30 These10) and control subjects (N Z 10). (A). SDF-1-TR1 mRNA levels
. No difference in SDF-1-TR2 mRNA levels was observed in IPF
Figure 3 CXCR4 mRNA expression in IPF (NZ 10) and control
subjects (NZ 10). Significantly higher CXCR4 mRNA levels were
observed in IPF patients compared to controls (P Z 0.001).
1540 K.M. Antoniou et al.receptors represent the basis for MSC homing to multiple
organs where they undergo a program of tissue-specific
differentiation.31 In our study we found that CXCR4 mRNA
was overexpressed in BM MSCs of IPF patients compared to
controls suggesting probably upregulation of this chemo-
kine receptor in an attempt of patients’ BM to respond to
the lung injury by MSC mobilization. We also found
increased levels of one SDF-1 mRNA transcript in BM MSCs of
IPF patients. However, this finding was not confirmed at the
protein level, as SDF-1 concentration in MSC supernatants
did not differ significantly between patients and controls.
The current paper has different limitations. Indeed, the
fact that our findings could be interpreted in more than one
way could be articulated as the major limitation of the
study. We therefore hypothesize a mobilization process of
CXCR4 overexpressing MSCs from the BM to peripheral
blood, and thence to the injured lung in response to a SDF-1
concentration gradient.32,33 However, the increased
expression of CXCR4 could also precede lung injury, at least
in part, and contributed to it in some way. Findings in the
current study do not appear to discriminate between these
two models. In addition, we have not excluded the possi-
bility that increased mobility of bone marrow cells is a key
early event in IPF. Therefore, changes in the expression of
other cytokines or their contribution to alternative key
mechanisms may occur once circulating bone marrow cells
reach the lungs.
The small number of cases constitutes a further limita-
tion of this study. The lack of statistical significance could
be due to lack of power in different occasions. Firstly, the
average number of cells is 50% lower among the patients
compared to controls, however does not reach statistical
significance. Secondly, but not less importantly, the age of
the controls may not be statistically different from the IPF
patients, however they are younger with fewer males. It
has been previously shown that aging may affect theproliferative potential of MSCs.34,35 An age-related defect
in the clonogenic and proliferative capacity of patient MSCs
cannot be excluded in the current study. However, it has
been showed that RA and IPF patients’ MSCs displayed age-
inappropriate relative telomere loss,19,36 suggesting that
the replicative capacity of cells speculates that the
defective growth potential of patient MSCs is due to inap-
propriate telomere loss.19 Furthermore, lower proportion
of smokers among the controls is a potential bias of the
current study, as it has been demonstrated that oxidative
stress is accelerating telomere length.37 Finally, there
aren’t data regarding sex influence on MSCs population
from ours or other studies.
The early nature of the IPF, compared to other pop-
ulations, could also be articulated as a potential limitation,
which is, may be, a strength. This is important because in
more advanced disease, the non-specific effects of hypoxia
might be expected to confound attempts to compare bone
marrow parameters with those in normal subjects.
A number of studies are in accordance with our
hypothesis. Specifically, in an experimental mouse model of
bleomycin-induced lung injury it was shown that BM derived
progenitor cells may participate in the fibrotic process in
response to locally produced chemokine signals as
neutralization of CXCL12 resulted in reduction of cell
recruitment and amelioration of lung fibrosis.9 Increased
expression of CXCL12 has been found in the lungs of
patients with IPF substantiating further the significance of
the CXCR4/CXCL12 axis in the pathogenesis of the fibrotic
process.32,33,38e40 It has also been reported that SDF-1
levels in BAL and peripheral blood specimens increase late
after bleomycin injury and this increase is accompanied by
an increase in CXCR4 expression in the lungs with a peak at
the second week after injury.10 These data are consistent
with the hypothesis that lungs with bleomycin-induced
injury stimulate a late increase in the expression of SDF-1,
which can be implicated in the mobilization of CXCR4þ
expressing BM MSCs.
However, verification in human IPF is rather limited.38e40
In the fibrogenic environment of the injured lung, CXCR4þ
cells may acquire a fibroblast phenotype finally contributing
to the fibrogenetic process.38 A histological study demon-
strated the presence of cells that coexpressed mesenchymal
and leukocyte markers in IPF lung.39 Finally, a recent study
suggests that the percentage of fibrocytes in circulation may
serve as a biomarker for the presence of fibrosis and
a potential biomarker for acute exacerbations.40 Further-
more, SDF-1/CXCL12 was increased in plasma from IPF
patients. A similar increase of this chemokine was also
recently reported, in agreement with the latter finding.38,39
A number of studies have investigated the possible
involvement of BM MSCs in the pathophysiology of inflam-
matory, degenerative, vascular and autoimmune disease.41
For example, it has been suggested that the BM may
contribute in pathophysiology of rheumatoid arthritis by
providing MSCs with altered properties in the affected
joints.42,43 However, recent data regarding the potential
use of MSCs for cartilage and bone repair in rheumatoid
arthritis showed that these patients have normal BM MSC
reserves and that culture expanded MSCs from RA patients
display normal differentiation capacity and proteomic
profile.20 In contrast, the cartilage and bone damage
Mesenchymal stem cells in IPF 1541associated with osteoarthritis has been attributed to the
impaired chondrogenic and adipogenic differentiation
potential of BM derived MSCs.44 In patients with systemic
sclerosis, the BM MSCs have not been shown to contribute
to the sclerosing process as they exhibit the normal
phenotypic, proliferative, differentiation potential and
immunosuppressive properties.45
To investigate the hypothesis that BM MSCs from IPF
patientsmay beprimarily involved in the pathogenesis of IPF,
we evaluated the expression of cytokines previously repor-
ted to be upregulated in the lungs of the affected subjects.
Our patient MSCs displayed normal VEGF, FGF, and TGF-b1
mRNA expression compared to healthy controls. This finding
suggests that the BM MSC population seems unlikely to be
primarily involved in lung injury but represents rather
a tissue repair cellular source. In favour of this hypothesis is
a recent study indicating that myelosuppression may
increase the lung susceptibility to bleomycin and transfer of
BM derived MSCs may display a protective action.11 In addi-
tion, intratracheal or systemic administration of MSCs
immediately after intratracheal bleomycin administration
decreased subsequent lung collagen accumulation, fibrosis
and levels of matrix metalloproteinases.46 Furthermore,
systemic MSC administration also decreased lung inflamma-
tion after endotoxin administration in mice.47e49 Based on
their anti-inflammatory and immunoregulatory properties,
BM MSCs are considered as potential therapeutic modalities
for autologous and allogeneic usage in immune-mediated
diseases including graft versus host disease.36,50
The complete absence of any difference between IPF
and normals in cytokines upregulated in the lung can be set
against the striking increase in a cytokine linked to mobi-
lization of bone marrow cells. However, we cannot be
certain that bone marrow cells are not contributing at some
level to lung injury, as we have selected a panel of cytokine
markers implicated in IPF. In addition, we have not
excluded the possibility that bone marrow cells without
cytokine upregulation in the marrow might, nonetheless,
play a key pathogenetic role in injury, simply by virtue of
enhanced mobilization.
In conclusion, these findings establish that the mobili-
zation of bone marrow cells could reasonably be interpo-
lated into a pathogenetic model for IPF, at one level or
another. In summary, the current study evaluates the
molecular characteristics of BM MSCs in patients with IPF.
The increased CXCR4 expression by patient MSCs suggests
that the BM is probably implicated in the pathophysiology
of IPF by mobilizing MSCs in response to or preceding lung
injury. The normal VEGF, FGF, and TGF-b1 mRNA expression
indicates that the BM derived MSCs is rather unlikely to be
the cellular population promoting the tissue injury in IPF, at
least by their upregulation. The potential role of the
abnormal lung microenvironment in the functional charac-
teristics of the recruited MSCs in IPF is another interesting
field for further investigation.Acknowledgments
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